CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
131I-metaiodobenzylguanidine (131I-MIBG) is a norepinephrine analog that concentrates in
adrenergic tissue and therefore holds promise for cell-specific treatment of neuroblastoma.
This is a dual institution, Phase II study of 131I-MIBG administered at the previously
defined maximum practical dose of 18 mCi/kg to children with relapsed or refractory
neuroblastoma.